FOR IMMEDIATE RELEASE
February 1, 2016

Contacts:

Zeb Kimmel, MD
Atlas5D, Inc.
One Broadway, 14th Floor
Cambridge, MA 02142
www.atlas5d.com

Tom Miller
GreyBird Ventures, LLC
www.greybirdventures.com

Atlas5D Announces $3 MM Series A Round from GreyBird Ventures, LLC

CAMBRIDGE, MA – Atlas5D, a leader in creating solutions to help people with reduced mobility live better and richer lives, announced a $3 million Series A venture capital investment from GreyBird Ventures, LLC, a venture firm that invests in early-stage companies developing products to accelerate the nascent trend of precision medicine. Atlas5D will use the infusion of capital to continue growing its team and expanding the business.

Atlas5D develops ambient sensors to precisely quantify aspects of human motion and behavior, such as speed and strength. The populations served range from very young to very old, encompass a wide variety of medical conditions such as multiple sclerosis (MS) and Parkinson’s, and include individuals who do not or cannot utilize wearable devices.

“Our flagship product, Echo5D, is the world’s first ambient sensor that sits passively on a shelf and precisely measures human movement and behavior, 24×7, even in the dark,” according to Zeb Kimmel, MD, CEO of Atlas5D. “With Echo5D, there’s nothing to remember, no need to wear any devices, no change in lifestyle, and no photos or videos. By providing insight and quantitative actionable information to patients, caregivers, and clinicians, across timeframes ranging from minutes to years, we offer the ability to track subtle changes and responses in health conditions. Our ultimate goal is to better tailor therapy and patient management strategies to individuals through improved monitoring of their patterns of motion.”

In 2015, Atlas5D began working with one of the world’s largest biotech companies and a luminary research hospital to engage people with Multiple Sclerosis (MS), a condition which can impair mobility, in testing the Echo5D technology within their own homes. MS is a chronic autoimmune disease that affects the nervous system of around a half-million individuals in the USA. Publications are in progress with expected release dates during 2016.

“GreyBird Ventures is excited to invest in innovative companies such as Atlas5D in the beginning of the era of precision medicine,” according to Tom Miller, one of the founders of GreyBird Ventures, LLC. “We view this trend as part of a continuous evolution of the practice of medicine and a revolution that will change everything we know about healthcare. Atlas5D, one of our first investments in this space, is a very early-stage company that is rapidly developing its technology to enable accurate and continuous monitoring of disease status and treatment effectiveness. We foresee their innovative use of sensors to measure activity while safeguarding privacy to make a great impact in this unexplored territory.”

Learn more at www.atlas5d.com and www.greybirdventures.com.